Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Kg

Martin Steegmaier

Matthias Grauert

Matthias Hoffmann

Flavio Solca

Anke Baum

Andreas Schoop

Gisela Schnapp

Trixi Brandl

Steffen Steurer

Jens Juergen Quant

Steffen Breitfelder

Bernd Krist

Christian Eickmeier

Rudolf Hauptmann

Harald Engelhardt

Heinz Stadtmueller

Florian Colbatzky

Frank Himmelsbach

Georg Dahmann

Alexander Pautsch

Walter Spevak

Martin Lenter

Norbert Redemann

Stephan Karl Zahn

Gerd Michael Munzert

Helmut Wittneben

Jens Jurgen Quant

Christoph Hoenke

Thorsten Lehmann-Lintz

Stefan Scheuerer

Darryl McConnell

Ulrich Reiser

Anthony S Prokopowicz

Frank Hilberg

Dirk Kessler

Bodo Betzemeier

Ulrike Weyer-Czernilofsky

Udo Maier

Maria Impagnatiello

Irene Waizenegger

Thomas Gerstberger

Christian Klein

Ralph Brueckner

Ulrich Guertler

Andreas Zoephel

Michael Gmachl

Charlotte Reither

Norbert Schweifer

Oliver Simon

Gerald Pohl

Peter Ettmayer

Andreas Mantoulidis

Eckhart Bauer

Ioannis Sapountzis

Guido Boehmelt

Matthias Hoffman

Anthony S Prokopowicz, Iii

Gisela Schapp

Lars Herfurth

Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I)  wherein the groups L, R, R, R, Rand Rhave the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Combinations for the treatment of diseases involving cell proliferation

The present invention relates to trisubstituted pyrimidines of formula (I) wherein

Pyrimidine derivatives

The present invention encompasses compounds of the general formula (1) in which

Thiazolyl-dihydro-indazoles

The present invention encompasses compounds of general formula (1) wherein the groups Rto R, L, Q and n are defined as in claim, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Chemical compounds

Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R, R, R, Rand Rmay have the meanings given in the claims and specification.

Methods of using pyridodihydropyrazinones

Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R, R, R, Rand Rhave the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Disclosed is the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

Dihydropteridinones for the treatment of cancer diseases

Disclosed are new dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and specification, the isomers thereof, intermediates and processes for preparing these dihydropteridinones and the use thereof as pharmaceutical compositions.

Dihydropteridinone compounds

Methods for treating diseases or conditions using dihydropteridinone compounds

The present invention relates to new 2-benzylaminodihydropteridinones of general formula (I) wherein the groups Rto R, Rand Rhave the meanings given in the claims and specification, the isomers thereof, methods of preparing these dihydropteridinones and their use as medicaments.

2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments

Disclosed are dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and specification, the pharmaceutical compositions, isomers, intermediates thereof and processes for preparing these dihydropteridinones. The compounds are useful the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.

Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same

The present invention relates to trisubstituted pyrimidines of formula (I) wherein0Rto Rare defined as in claim, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Thiazolyl-dihydro-indazole

Pyridodihydropyraziones, process for their manufacture and use thereof as medicaments

The present invention encompasses compounds of general formula (1) wherein

2,4-diaminopyrimidines useful for treating cell proliferation diseases

Growing community of inventors

Vienna, Austria

Martin Steegmaier